This document summarizes the results of a large European randomized controlled trial that evaluated the effect of prostate cancer screening using prostate-specific antigen (PSA) testing on death rates from prostate cancer. Over 160,000 men ages 55-69 were randomly assigned to either a screening group that was offered PSA screening every 4 years or a control group that did not receive screening. After a median follow-up of 9 years, the cumulative incidence of prostate cancer was higher in the screening group (8.2%) than the control group (4.8%). The rate of death from prostate cancer was 20% lower in the screening group compared to the control group. However, screening led to overdiagnosis, with 1410 men needing